European Knowledge Centre opened in the UK - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

European Knowledge Centre opened in the UK


Eisai (Japan) has opened its new European Knowledge Centre in Hertfordshire (UK) after investing approximately 117 million euro in the region to help develop new medicines for Alzheimer's Disease, Parkinson's Disease and epilepsy, as well as new treatments for cancer. The company's first ever European manufacturing facility will also be based at the centre.

"This is an exciting day for the company," said Haruo Naito, President and CEO of the company. "The newly opened centre will not only act as a hub for managing our current business across Europe; it will play an important role in supporting our operations in driving further growth for the company in Europe — one of our key investment markets."

The opening of the facility was attended by the Japanese ambassador to the UK, His Excellency Shin Ebihara, who in a press release said he was hopeful that the combined knowledge of the UK and Japan would "add a new page to the long history and excellent economic relationship between the countries." Alzheimer's disease campaigner and best-selling author Terry Pratchett was also present.

"We need to speed up research and, incidentally, the speed in which successful discoveries get to patients. Alzheimer's research started late compared with many other diseases and the wave is already breaking," said Pratchett in a press release from Eisai. "I hope everyone employed in the centre works overtime!"

www.eisai.co.jp

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here